PRTK - Paratek Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.4400
+0.1400 (+3.26%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close4.3000
Open4.3000
Bid4.2500 x 900
Ask4.5000 x 1400
Day's Range4.2500 - 4.4900
52 Week Range2.5000 - 5.8900
Volume212,539
Avg. Volume717,420
Market Cap191.506M
Beta (5Y Monthly)1.51
PE Ratio (TTM)N/A
EPS (TTM)-3.4400
Earnings DateMay 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateOct 31, 2014
1y Target Est15.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Paratek Pharmaceuticals Announces Change to Time of 2020 Annual Meeting of Stockholders

    Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced its virtual 2020 Annual Meeting of Stockholders (the “Annual Meeting”) will now be held at 9:00 a.m. Eastern Time. As described in the proxy materials previously distributed for the Annual Meeting, stockholders as of the close of business on April 13, 2020, the record date, may attend the meeting virtually via the Internet at www.virtualshareholdermeeting.com/PRTK2020 by entering the 16-digit control number found in such proxy materials or, for stockholders that hold their shares in “street name,” by following the instructions provided by each such stockholder’s bank or brokerage firm.

  • GlobeNewswire

    Paratek Pharmaceuticals to Present at Jefferies 2020 Virtual Healthcare Conference

    Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the Company will present at the Jefferies 2020 Virtual Healthcare Conference, Wednesday, June 3, 2020 at 8:00 a.m. ET. To access the live webcast of Paratek's presentation, please visit http://wsw.com/webcast/jeff126/prtk/. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.

  • GlobeNewswire

    Paratek Pharmaceuticals to Present at Bank of America Securities 2020 Health Care Conference

    Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the Company will present at Bank of America Securities 2020 Health Care Conference, Wednesday, May 13, 2020 at 11:40 a.m. ET. To access the live webcast of Paratek's presentation, please visit http://www.veracast.com/webcasts/bofa/healthcare2020/id57206441686.cfm. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.

  • Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Tops Revenue Estimates
    Zacks

    Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Tops Revenue Estimates

    Paratek (PRTK) delivered earnings and revenue surprises of 20.48% and 2.15%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga

    Paratek Pharmaceuticals: Q1 Earnings Insights

    Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) rose 2.1% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share were up 40.00% year over year to ($0.66), which beat the estimate of ($0.80).Revenue of $7,920,000 higher by 395.62% year over year, which beat the estimate of $7,460,000.Outlook Earnings guidance hasn't been issued by the company for now.View more earnings on PRTKRevenue guidance hasn't been issued by the company for now.Price Action Company's 52-week high was at $5.8952-week low: $2.50Price action over last quarter: Up 9.95%Company Profile Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. Omadacycline is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. Sarecycline is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.See more from Benzinga * Recap: New Age Beverages Q1 Earnings * Recap: Synchronoss Technologies Q1 Earnings * Arbutus Biopharma: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GlobeNewswire

    Paratek Pharmaceuticals Announces First Quarter 2020 Total Revenues of $7.9 Million including NUZYRA® (omadacycline) Net Sales of $7.3 Million

    -- Announced Initiation of Funding from BARDA for All FDA Required Post-Marketing Studies and Security Requirements and U.S. Onshoring of an Additional Manufacturing.

  • GlobeNewswire

    Paratek Pharmaceuticals to Report First Quarter 2020 Financial Results on May 11, 2020

    Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced the Company will host a conference call and live audio webcast on Monday, May 11, 2020 at 8:30 a.m. EDT to report its financial results for the quarter ended March 31, 2020 and provide a corporate update. The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use.

  • Will Paratek Pharmaceuticals Continue to Surge Higher?
    Zacks

    Will Paratek Pharmaceuticals Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor Paratek Pharmaceuticals

  • GlobeNewswire

    Paratek Pharmaceuticals Announces Initiation of Funding from BARDA for All FDA Required Post-marketing Studies for NUZYRA• (omadacycline)

    Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has initiated funding to support all of the U.S. Food and Drug Administration (FDA) post-marketing requirements associated with the approval of NUZYRA including pneumonia and pediatric studies as well as the five-year post-marketing bacterial surveillance study. In connection with the FDA approval of NUZYRA in October 2018, the FDA required that Paratek complete post-marketing pediatric studies examining the safety and efficacy of NUZYRA in children ages eight to 17 years.

  • GlobeNewswire

    Paratek Pharmaceuticals Announces Initiation of Funding from BARDA for Security Requirements and U.S. Onshoring of the Manufacturing Supply Chain for NUZYRA• (omadacycline)

    Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and for other public health threats for civilian, government and military use, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has initiated funding to support the onshoring of Paratek manufacturing activities for NUZYRA. In December 2019, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, awarded Paratek a five-year contract, valued at up to $285 million, to support: 1) the development of NUZYRA for the treatment of pulmonary anthrax; 2) all of the U.S. Food and Drug Administration post-marketing requirements associated with the initial NUZYRA approval; 3) U.S. onshoring and manufacturing security requirements and 4) the procurement of up to 10,000 treatment courses of NUZYRA for the treatment of anthrax.

  • Paratek Pharmaceuticals, Inc. Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
    Simply Wall St.

    Paratek Pharmaceuticals, Inc. Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?

    Shareholders in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) had a terrible week, as shares crashed 37% to US$2.92 in...

  • Thomson Reuters StreetEvents

    Edited Transcript of PRTK earnings conference call or presentation 25-Feb-20 9:30pm GMT

    Q4 2019 Paratek Pharmaceuticals Inc Earnings Call

  • GlobeNewswire

    Paratek Pharmaceuticals Announces the Submission of the pre-Emergency Use Authorization Application to the FDA for NUZYRA• (omadacycline)

    Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that a pre-emergency use authorization (EUA) application for NUZYRA• (omadacycline) has been submitted to the U.S. Food and Drug Administration (FDA). With a pre-EUA, FDA could allow for the potential use of NUZYRA during a declared emergency under emergency use authorization for the treatment and prophylaxis of pulmonary anthrax in a public health emergency.

  • GlobeNewswire

    Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that on February 28, 2020, the Company granted stock options and restricted stock units to two new employees of the Company. The stock options are to acquire, in the aggregate, 21,100 shares of the Company’s common stock at a per share exercise price of $4.78, the closing sales price on February 28, 2020, and shall vest over a four-year vesting period, under which 25% of the shares will vest after 12 months of employment, with the remaining shares vesting monthly thereafter over the remaining 36-month period, subject to the employee’s continuous service.

  • Paratek Pharmaceuticals, Inc. Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates
    Simply Wall St.

    Paratek Pharmaceuticals, Inc. Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

    The investors in Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK) will be rubbing their hands together with glee today...

  • GlobeNewswire

    Paratek Pharmaceuticals to Present at the SVB Leerink 9th Annual Global Healthcare Conference

    Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the Company will present at SVB Leerink 9th Annual Global Healthcare Conference today, Wednesday, February 26, 2020 at 3:00 p.m. ET at the Lotte New York Palace Hotel in New York. To access the live webcast of Paratek's presentation, please visit http://wsw.com/webcast/svbleerink34/prtk/. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.

  • Paratek Pharmaceuticals (PRTK) Reports Q4 Loss, Tops Revenue Estimates
    Zacks

    Paratek Pharmaceuticals (PRTK) Reports Q4 Loss, Tops Revenue Estimates

    Paratek (PRTK) delivered earnings and revenue surprises of 21.36% and 87.59%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Paratek Pharmaceuticals Announces Full Year 2019 Total Revenues of $16.5 Million including NUZYRA® (omadacycline) Net Sales of $11.5 Million

    -- Paratek Expects Full Year 2020 Total Revenues to be Between $75 and $80 Million including NUZYRA Net Sales of Approximately $66 Million   -- Paratek Now Anticipates its Cash.

  • GlobeNewswire

    Paratek Announces License Grant to Almirall for SEYSARA® (sarecycline) for Greater China Region

    Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced the Company has entered into a license grant with Almirall (ALM) for SEYSARA® (sarecycline) for the greater China region, which includes the Peoples Republic of China, Hong Kong, and Macau. Under the terms of the agreement, Paratek will earn high single-digit royalties on net sales in the greater China region. Almirall plans to develop sarecycline for acne in China, with a potential submission to the China National Medical Products Administration in 2023.

  • Is Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) A Volatile Stock?
    Simply Wall St.

    Is Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) A Volatile Stock?

    If you own shares in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) then it's worth thinking about how it contributes to...

  • GlobeNewswire

    Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020

    Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced the Company will host a conference call and live audio webcast on Tuesday, February 25, 2020 at 4:30 p.m. EDT to report its financial results for the quarter and year ended December 31, 2019 and provide a corporate update. Domestic investors wishing to participate in the call should dial: 877-407-0792 and international investors should dial: 201-689-8263. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics.

  • Find Cheap Highly-Ranked Stocks Trading Under $10 for 2020
    Zacks

    Find Cheap Highly-Ranked Stocks Trading Under $10 for 2020

    Find Cheap Highly-Ranked Stocks Trading Under $10 for 2020

  • Are Options Traders Betting on a Big Move in Paratek Pharmaceuticals (PRTK) Stock?
    Zacks

    Are Options Traders Betting on a Big Move in Paratek Pharmaceuticals (PRTK) Stock?

    Investors need to pay close attention to Paratek Pharmaceuticals (PRTK) stock based on the movements in the options market lately.

  • Why this King of Prussia biopharma's stock rose 32% Thursday
    American City Business Journals

    Why this King of Prussia biopharma's stock rose 32% Thursday

    Paratek Pharmaceuticals's stock closed up 32% Thursday after the biopharmaceutical company announced it was awarded a five-year contract worth up to $285 million from the federal government. The funds will support the development of the company's antibiotic Nuzyra as a treatment of pulmonary anthrax. The contract was awarded under the Biomedical Advanced Research and Development Authority's, or BARDA, Project BioShield program.

  • Benzinga

    The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 18) 10X Genomics Inc (NASDAQ: TXG ) Acceleron Pharma Inc ...